Fondazione IRCCS San Gerardo Dei Tintori

At Fondazione IRCCS San Gerardo Dei Tintori, a major share of research focuses on neoplasms and blood cancers, with studies spanning breast cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer, leukemias, and lymphomas. These trials are designed to test new treatment strategies, improve outcomes after standard therapy, and explore more effective approaches for advanced or hard-to-treat disease.

• Breast cancer, lung cancer, and ovarian cancer studies evaluating new ways to improve treatment response
• Acute and chronic leukemias plus lymphoma research aimed at better disease control and relapse prevention
• Solid tumor trials focused on advanced disease, surgical settings, and post-treatment outcomes

Much of this work centers on comparing emerging therapies with current standards to help refine care for patients with advanced cancers and hematologic malignancies.

The site also conducts extensive research in immune system diseases, including inflammatory bowel disease, systemic lupus erythematosus, primary sclerosing cholangitis, primary biliary cholangitis, and graft-versus-host disease. These trials aim to improve symptom control, reduce inflammation, and evaluate safer or more durable treatment options for chronic immune-mediated conditions.

• Ulcerative colitis and Crohn’s disease studies assessing better control of intestinal inflammation
• Autoimmune liver disease research focused on pruritus, fatigue, and long-term disease management
• Transplant-related complications such as acute graft-versus-host disease and thrombotic microangiopathy

This area reflects a strong interest in improving quality of life while also testing treatments that may better balance effectiveness and safety.

Clinical trials at the Monza hospital include important work in respiratory tract diseases, cardiovascular diseases, and pulmonary vascular disorders. Research covers lung cancer, pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary arterial hypertension, and myocardial infarction, with a clear focus on testing therapies that may improve survival, breathing, and cardiovascular recovery.

• Non-small cell lung cancer and small-cell lung cancer trials evaluating new treatment combinations and targeted approaches
• Idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and related lung scarring conditions
• Acute myocardial infarction and pulmonary arterial hypertension studies aimed at reducing complications and improving clinical outcomes

These studies highlight the site’s role in advancing care for serious heart and lung conditions where better treatment options are still needed.

Another active research area involves nervous system diseases and mental disorders, especially Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, traumatic brain injury, and major depressive disorder. The trials in this field are intended to improve disease management, support cognitive function, and assess approaches for symptom relief and long-term care.

• Alzheimer’s disease and mild cognitive impairment studies focused on slowing decline and supporting cognition
• Parkinson’s disease and multiple sclerosis research exploring better symptom management
• Depression studies examining treatment effectiveness and safer discontinuation strategies

At Fondazione IRCCS San Gerardo Dei Tintori, this field combines neurological and psychiatric research to address both brain health and everyday functioning.

There is also substantial activity in digestive system diseases and related liver disorders, including ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis, primary biliary cholangitis, and chronic liver disease. These trials seek to improve inflammation control, reduce symptoms such as itch and fatigue, and evaluate therapies that may better support long-term digestive and liver health.

• Inflammatory bowel disease studies aimed at improving remission and maintenance of control
• Cholestatic liver disease research focused on symptom relief and disease stabilization
• Colorectal and other gastrointestinal cancer studies addressing treatment effectiveness

This area reflects a broad commitment to both chronic digestive disorders and cancer care, with an emphasis on practical benefits for patients.

The site contributes to trials in congenital, hereditary, and neonatal diseases as well as other rare disorders, including mucopolysaccharidosis, glycogen storage disease, sickle cell disease, and pediatric leukemia. These studies are generally aimed at improving outcomes in children and young people with conditions that often have limited treatment options.

• Pediatric leukemia and lymphoma trials focused on better disease control and survival
• Rare metabolic disorders such as mucopolysaccharidosis and glycogen storage disease
• Inherited blood disorders and other uncommon conditions where new therapies are needed

These studies show a strong interest in helping younger patients and families facing complex diseases that require specialized care.

Research at the site also extends to kidney diseases, immune-mediated blood disorders, and broader supportive care questions. Trials include IgA nephropathy, lupus nephritis, myelofibrosis, and immune thrombocytopenia, with goals that range from reducing proteinuria to improving symptom burden and long-term disease management.

• IgA nephropathy and lupus nephritis studies evaluating kidney protection and inflammation control
• Myelofibrosis and thrombocytopenia research focused on treatment effectiveness and symptom reduction
• Supportive care trials addressing fatigue, cognitive symptoms, and quality of life

This work complements the site’s broader disease portfolio by addressing both organ-specific disease activity and day-to-day patient needs.